Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RICHARD E CHAMPLIN and QAISER BASHIR.
RICHARD E CHAMPLIN
Connection Strength
7.811
QAISER BASHIR
  1. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther. 2024 Feb; 30(2):205.e1-205.e12.
    View in: PubMed
    Score: 0.234
  2. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
    View in: PubMed
    Score: 0.216
  3. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022 01; 57(1):51-56.
    View in: PubMed
    Score: 0.207
  4. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 01; 36(1):155-164.
    View in: PubMed
    Score: 0.204
  5. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020 02 06; 135(6):449-452.
    View in: PubMed
    Score: 0.184
  6. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.
    View in: PubMed
    Score: 0.177
  7. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.
    View in: PubMed
    Score: 0.173
  8. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.
    View in: PubMed
    Score: 0.163
  9. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.156
  10. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93.
    View in: PubMed
    Score: 0.135
  11. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.
    View in: PubMed
    Score: 0.132
  12. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.117
  13. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.109
  14. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.
    View in: PubMed
    Score: 0.105
  15. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma. 2012 May; 53(5):915-9.
    View in: PubMed
    Score: 0.105
  16. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.
    View in: PubMed
    Score: 0.103
  17. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1067-71.
    View in: PubMed
    Score: 0.097
  18. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol. 2011 Feb 01; 29(4):e79-80.
    View in: PubMed
    Score: 0.097
  19. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84.
    View in: PubMed
    Score: 0.095
  20. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther. 2024 Jun 07.
    View in: PubMed
    Score: 0.062
  21. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024 May 17; 14(1):82.
    View in: PubMed
    Score: 0.062
  22. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv. 2024 Mar 23.
    View in: PubMed
    Score: 0.061
  23. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 Mar 12; 8(5):1128-1136.
    View in: PubMed
    Score: 0.061
  24. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 Mar 06.
    View in: PubMed
    Score: 0.061
  25. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 Feb 14.
    View in: PubMed
    Score: 0.061
  26. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569.
    View in: PubMed
    Score: 0.061
  27. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.
    View in: PubMed
    Score: 0.060
  28. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672.
    View in: PubMed
    Score: 0.060
  29. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023 Oct 24; 7(20):6196-6205.
    View in: PubMed
    Score: 0.060
  30. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther. 2023 Dec; 29(12):770.e1-770.e6.
    View in: PubMed
    Score: 0.059
  31. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.
    View in: PubMed
    Score: 0.059
  32. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.
    View in: PubMed
    Score: 0.058
  33. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.
    View in: PubMed
    Score: 0.058
  34. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant. 2023 09; 58(9):1000-1007.
    View in: PubMed
    Score: 0.058
  35. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.
    View in: PubMed
    Score: 0.058
  36. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.
    View in: PubMed
    Score: 0.057
  37. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.
    View in: PubMed
    Score: 0.056
  38. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol. 2023 02; 98(2):E35-E37.
    View in: PubMed
    Score: 0.056
  39. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198.
    View in: PubMed
    Score: 0.056
  40. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.
    View in: PubMed
    Score: 0.056
  41. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica. 2022 10 01; 107(10):2496-2500.
    View in: PubMed
    Score: 0.055
  42. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.
    View in: PubMed
    Score: 0.055
  43. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10.
    View in: PubMed
    Score: 0.055
  44. Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Am J Health Syst Pharm. 2022 06 07; 79(12):1011-1018.
    View in: PubMed
    Score: 0.054
  45. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10.
    View in: PubMed
    Score: 0.054
  46. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.
    View in: PubMed
    Score: 0.054
  47. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.
    View in: PubMed
    Score: 0.054
  48. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 07; 28(7):395.e1-395.e11.
    View in: PubMed
    Score: 0.054
  49. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8.
    View in: PubMed
    Score: 0.053
  50. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022 03 03; 139(9):1289-1301.
    View in: PubMed
    Score: 0.053
  51. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214.
    View in: PubMed
    Score: 0.052
  52. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.
    View in: PubMed
    Score: 0.052
  53. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457.
    View in: PubMed
    Score: 0.052
  54. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.
    View in: PubMed
    Score: 0.052
  55. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 11 01; 27(21):5847-5856.
    View in: PubMed
    Score: 0.051
  56. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12.
    View in: PubMed
    Score: 0.051
  57. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.
    View in: PubMed
    Score: 0.051
  58. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.
    View in: PubMed
    Score: 0.050
  59. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant. 2021 08; 56(8):2005-2012.
    View in: PubMed
    Score: 0.050
  60. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.
    View in: PubMed
    Score: 0.050
  61. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.
    View in: PubMed
    Score: 0.049
  62. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.049
  63. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605.
    View in: PubMed
    Score: 0.049
  64. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.049
  65. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837.
    View in: PubMed
    Score: 0.048
  66. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
    View in: PubMed
    Score: 0.048
  67. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. 2020 Oct; 95(10):E267-E269.
    View in: PubMed
    Score: 0.048
  68. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.047
  69. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.
    View in: PubMed
    Score: 0.047
  70. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.
    View in: PubMed
    Score: 0.046
  71. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.046
  72. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.
    View in: PubMed
    Score: 0.045
  73. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
    View in: PubMed
    Score: 0.045
  74. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.
    View in: PubMed
    Score: 0.045
  75. Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.
    View in: PubMed
    Score: 0.044
  76. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.043
  77. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant. 2019 07; 25(7):1347-1354.
    View in: PubMed
    Score: 0.043
  78. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.043
  79. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019 05; 67(2):51-55.
    View in: PubMed
    Score: 0.043
  80. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
    View in: PubMed
    Score: 0.043
  81. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74.
    View in: PubMed
    Score: 0.043
  82. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093.
    View in: PubMed
    Score: 0.042
  83. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.042
  84. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.
    View in: PubMed
    Score: 0.042
  85. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 06; 54(6):839-848.
    View in: PubMed
    Score: 0.042
  86. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
    View in: PubMed
    Score: 0.042
  87. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.
    View in: PubMed
    Score: 0.042
  88. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.
    View in: PubMed
    Score: 0.041
  89. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.
    View in: PubMed
    Score: 0.040
  90. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma. 2018 08; 59(8):1905-1912.
    View in: PubMed
    Score: 0.040
  91. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res. 2018 Apr; 27(4):979-985.
    View in: PubMed
    Score: 0.040
  92. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.
    View in: PubMed
    Score: 0.039
  93. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518.
    View in: PubMed
    Score: 0.038
  94. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.038
  95. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.
    View in: PubMed
    Score: 0.038
  96. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.038
  97. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670.
    View in: PubMed
    Score: 0.038
  98. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.038
  99. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion. 2017 04; 57(4):1052-1057.
    View in: PubMed
    Score: 0.037
  100. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Apr; 23(4):581-587.
    View in: PubMed
    Score: 0.037
  101. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268.
    View in: PubMed
    Score: 0.037
  102. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292.
    View in: PubMed
    Score: 0.037
  103. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.
    View in: PubMed
    Score: 0.037
  104. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2159-2164.
    View in: PubMed
    Score: 0.036
  105. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.
    View in: PubMed
    Score: 0.036
  106. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117.
    View in: PubMed
    Score: 0.036
  107. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.036
  108. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.
    View in: PubMed
    Score: 0.036
  109. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
    View in: PubMed
    Score: 0.035
  110. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
    View in: PubMed
    Score: 0.035
  111. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7.
    View in: PubMed
    Score: 0.035
  112. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.
    View in: PubMed
    Score: 0.034
  113. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
    View in: PubMed
    Score: 0.034
  114. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.
    View in: PubMed
    Score: 0.033
  115. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1413-7.
    View in: PubMed
    Score: 0.033
  116. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1405-1412.
    View in: PubMed
    Score: 0.033
  117. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.033
  118. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.
    View in: PubMed
    Score: 0.032
  119. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015 Mar; 56(3):602-7.
    View in: PubMed
    Score: 0.032
  120. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5.
    View in: PubMed
    Score: 0.031
  121. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
    View in: PubMed
    Score: 0.030
  122. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.
    View in: PubMed
    Score: 0.029
  123. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.
    View in: PubMed
    Score: 0.028
  124. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013 Feb; 19(2):214-20.
    View in: PubMed
    Score: 0.028
  125. Fifty years of melphalan use in hematopoietic stem cell?transplantation. Biol Blood Marrow Transplant. 2013 Mar; 19(3):344-56.
    View in: PubMed
    Score: 0.027
  126. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.027
  127. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8.
    View in: PubMed
    Score: 0.027
  128. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.
    View in: PubMed
    Score: 0.027
  129. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012 Jul 15; 118(14):3549-55.
    View in: PubMed
    Score: 0.026
  130. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.
    View in: PubMed
    Score: 0.026
  131. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.